Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study.
Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study.
复制标题
DOI：
10.1016/j.cyto.2021.155627
复制
发表时间：
2021-10
期刊：
影响因子：
3.8
通讯作者：
Shmidt AE
中科院分区：
文献类型：
--
作者：
Avdeev SN;Trushenko NV;Tsareva NA;Yaroshetskiy AI;Merzhoeva ZM;Nuralieva GS;Nekludova GV;Chikina SY;Gneusheva TY;Suvorova OA;Shmidt AE
COVID-19严重病程的主要病理生理机制之一是与肺组织进行性损伤和多器官功能障碍相关的高炎症综合征。IL-17已被认为参与高炎症综合征。评估IL-17抑制剂奈他单抗在重度COVID-19患者中的疗效和安全性。研究设计.在我们的回顾性病例对照研究中，我们评估了奈他单抗在重症监护室（ICU）外的重症COVID-19住院患者中的疗效。实验组患者接受标准治疗和120 mg剂量的netakimab皮下注射。171名重症COVID-19患者入组了我们的研究，其中88名接受了奈他单抗治疗。治疗第3天，与对照组相比，奈他单抗组的体温、SpO 2/FiO 2、NEWS 2评分和CRP均显著改善。其他临床结局，如转入ICU（11.4% vs 9.6%）、需要机械通气（10.2% vs 9.6%）、28天死亡率（10.2% vs 8.4%），两组之间无差异。在严重COVID-19住院患者中，抗IL-17治疗可能会减轻炎症反应并改善氧合，但不会影响机械通气的需求和死亡率。
One of the main pathophysiological mechanisms underlying the severe course of COVID-19 is the hyper-inflammatory syndrome associated with progressive damage of lung tissue and multi-organ dysfunction. IL-17 has been suggested to be involved in hyper-inflammatory syndrome. To evaluate the efficacy and safety of the IL-17 inhibitor netakimab in patients with severe COVID-19. Study design. In our retrospective case-control study we evaluated the efficacy of netakimab in hospitalized patients with severe COVID-19 outside the intensive care unit (ICU). Patients in the experimental group were treated with standard of care therapy and netakimab at a dose of 120 mg subcutaneously. 171 patients with severe COVID-19 were enrolled in our study, and 88 of them received netakimab. On the 3 day of therapy, body temperature, SpO2/FiO2, NEWS2 score, and CRP improved significantly in the netakimab group compared to the control group. Other clinical outcomes such as transfer to ICU (11.4% vs 9.6%), need for mechanical ventilation (10.2% vs 9.6%), 28-day mortality (10.2% vs 8.4%), did not differ between the groups. In hospitalized patients with severe COVID-19, anti-IL-17 therapy might mitigate the inflammatory response and improve oxygenation, but do not affect the need for mechanical ventilation and mortality.
登录
查看更多内容
DOI：
10.1164/rccm.201410-1782oc
发表时间：
2016-02-15
影响因子：
24.7
作者：
Muir, Roshell;Osbourn, Megan;Ingram, Rebecca J.
通讯作者：
Ingram, Rebecca J.
影响因子：
4.5
作者：
Shibabaw T
通讯作者：
Shibabaw T
DOI：
10.1056/nejmra2026131
发表时间：
2020-12-03
期刊：
The New England journal of medicine
影响因子：
--
作者：
Fajgenbaum DC;June CH
通讯作者：
June CH
影响因子：
13.3
作者：
Henderson, Lauren A.;Canna, Scott W.;Nigrovic, Peter A.
通讯作者：
Nigrovic, Peter A.
影响因子：
6.5
作者：
Wan, Suxin;Yi, Qingjie;Gao, Cailiang
通讯作者：
Gao, Cailiang